Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 70/100

Failure Rate

3.8%

1 terminated/withdrawn out of 26 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

13 recruiting

Enrollment Performance

Analytics

Phase 1
25(96.2%)
Phase 2
1(3.8%)
26Total
Phase 1(25)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (26)

Showing 20 of 26 trials
NCT06926868Phase 2Recruiting

A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)

Role: collaborator

NCT07021066Phase 1Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M05D1 in Subjects With Solid Tumors

Role: lead

NCT06293898Phase 1Recruiting

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

Role: lead

NCT07080242Phase 1Recruiting

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Role: lead

NCT05983432Phase 1Recruiting

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Role: lead

NCT06714591Phase 1Recruiting

Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1

Role: lead

NCT06714617Phase 1Active Not Recruiting

Evaluate BL-M17D1 in Patients w/HER2-Expressing/Mutant Advanced or Metastatic Solid Tumors

Role: lead

NCT05623982Phase 1Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Role: collaborator

NCT04794972Phase 1Recruiting

A Study of GNC-039, a Tetra-specific Antibody, in Participants With Relapsed/Refractory or Metastatic Solid Tumors

Role: collaborator

NCT05627856Phase 1Active Not Recruiting

A Study of GNC-038 Injection in Patients With Relapsed or Refractory NK/ T-cell Lymphoma, AITL, and Other NHL

Role: collaborator

NCT05470348Phase 1Recruiting

A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

Role: collaborator

NCT05461768Phase 1Recruiting

A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Low Expression Breast Cancer and Other Solid Tumors

Role: collaborator

NCT04603287Phase 1Active Not Recruiting

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Role: collaborator

NCT04606472Phase 1Active Not Recruiting

A Study of SI-B003, a PD-1/CTLA-4 Bispecific Antibody, in Patients With Advanced Solid Tumors

Role: collaborator

NCT05192486Phase 1Active Not Recruiting

A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)

Role: collaborator

NCT05631964Phase 1Recruiting

Phase I Clinical Study of BL-M07D1 in Locally Advanced or Metastatic Digestive Tract Tumors and Other Solid Tumors

Role: collaborator

NCT05393427Phase 1Active Not Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors

Role: collaborator

NCT05262491Phase 1Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor

Role: collaborator

NCT05385692Phase 1Active Not Recruiting

A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors or Other Solid Tumors

Role: collaborator

NCT05194982Phase 1Recruiting

A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor

Role: collaborator